Yuhan, Ubix ink licensing deal; Xenpozyme's royalty deal
Plus, news about Ipsen, Exelixis, Innovent, Codexis, Crosswalk Therapeutics and J&J:
Yuhan licenses prostate cancer drug: The biotech will pay Seoul …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
